

**SFT Annual Meeting 2013**

## **Risk assessment: Learning from pharmacological toxicology**

Drug toxicity remains a high profile issue at a time when the recent publicized controversies surrounding the safety of some drugs have contributed to a public perception that the drug safety system is in crisis and, in parallel, Sweden is deprived of the centre of this competence after the closure of the AstraZeneca Safety Assessment laboratory in Södertälje.

The SFT annual meeting 2013 will be dedicated to the potential of new biology and technology to contribute to the development of predictive strategies for the risk assessment and use of safe drugs. The presentations will describe and discuss the complex and multidisciplinary science of drug safety assessment that shares the principles with other branches of toxicology.

After lunch, the new initiative to form the Swedish Toxicology Sciences Institute (SweTox) will be presented and open for discussion.

We would like the SFT annual meeting to be the number one arena for toxicological networking and informal cross-sector contacts. Please take the opportunity to meet your new and old friends and colleagues during lunch and coffee breaks.

Most welcome!

Registration at the SFT web is mandatory before 14 March, 2013

Please fill in the form at <http://toxikolog.se/arsmoten/>

For questions: please contact Jennie Andersson, SFT secretary at [info@toxikolog.se](mailto:info@toxikolog.se)

Society members – Free

Non-members – 250 kr (students/retired: 100 kr), to be paid at entrance.

# Agenda

- 9.00 – 9.30 Coffee
- 9.30 – 9.45 **Opening of the meeting**  
*Dr Mattias Öberg, President of the Swedish SOT*
- 9.45 – 10.20 **Basic principles of the safety assessment of drugs**  
*Dr Björn Dahl, AstraZeneca*
- 10.20 – 11.10 **The use and impact of novel technologies for risk assessment of pharmaceuticals**  
In silico modeling, stem cells and multidimensional in vitro models  
*Professor Ian Cotgreave, AstraZeneca*
- The application of safety biomarkers to risk assessment of drugs  
*Dr Ina Schuppe Koistinen, Science for Life Laboratory / AstraZeneca Translational Science Centre*
- 11.10 – 11.35 **What is the predictive value of cancer studies?**  
*Dr Anna-Lena Berg, Medical Products Agency*
- 11.35 – 12.00 **Current regulatory discussion on carcinogenicity testing of pharmaceuticals**  
*Dr Ulla Wändel-Liminga, Medical Products Agency*
- 12.00 – 13.00 Lunch
- 13.00 – 13.30 **How can contemporary toxicology and safety/risk assessment learn from and fertilize drug development?**  
*Panel discussion*
- 13.30 – 14.00 **Årsmötesförhandlingar** [in Swedish]
- 14.00 – 14.30 Coffee
- 14.30 – 14.50 **ERT, European Registered Toxicologist** [in Swedish]  
Charlotte Nilsson, Marie Haag Grönlund
- 14.50 – 16.00 **Swedish Toxicology Sciences Institute, SweTox** [in Swedish]  
SweTox project group